ME01514B - Histone deacetylase inhibitors with combined activity on class-l and class-ll B histone deacetylases in combination with proteasome inhibitors - Google Patents

Histone deacetylase inhibitors with combined activity on class-l and class-ll B histone deacetylases in combination with proteasome inhibitors

Info

Publication number
ME01514B
ME01514B MEP-2013-15A MEP1513A ME01514B ME 01514 B ME01514 B ME 01514B ME P1513 A MEP1513 A ME P1513A ME 01514 B ME01514 B ME 01514B
Authority
ME
Montenegro
Prior art keywords
class
inhibitors
histone
combination
combined activity
Prior art date
Application number
MEP-2013-15A
Other languages
Unknown language (me)
Inventor
Janine Arts
Peter Willem Jan Hellemans
Michel Marie François JANICOT
Martin John Page
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2007/059518 external-priority patent/WO2008031817A2/en
Publication of ME01514B publication Critical patent/ME01514B/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ovaj pronalazak se odnosi na inhibitore histonske deacetilaze (HDAC) sa spojenom aktivnosti protiv histonskih deacetilaza iz klase-I i klase-II. Pronalazak se odnosi na kombinacije i kompozicije koje obuhvataju pomenute inhibitore, kao i na njihovu upotrebu, kao lekove, na primer kao lek koji inhibira hematopoetske tumore poput limfoma i leukemija.The present invention relates to histone deacetylase (HDAC) inhibitors with coupled activity against class-I and class-II histone deacetylases. The invention relates to combinations and compositions comprising said inhibitors as well as their use as medicaments, for example as a medicament that inhibits hematopoietic tumors such as lymphomas and leukemias.

MEP-2013-15A 2006-09-15 2007-09-11 Histone deacetylase inhibitors with combined activity on class-l and class-ll B histone deacetylases in combination with proteasome inhibitors ME01514B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06120726 2006-09-15
US91589507P 2007-05-03 2007-05-03
PCT/EP2007/059518 WO2008031817A2 (en) 2006-09-15 2007-09-11 Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors
EP07803397A EP2066327B1 (en) 2006-09-15 2007-09-11 Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors

Publications (1)

Publication Number Publication Date
ME01514B true ME01514B (en) 2014-04-20

Family

ID=41040414

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2013-15A ME01514B (en) 2006-09-15 2007-09-11 Histone deacetylase inhibitors with combined activity on class-l and class-ll B histone deacetylases in combination with proteasome inhibitors

Country Status (12)

Country Link
CN (1) CN101516374B (en)
BR (1) BRPI0716992A2 (en)
DK (1) DK2066327T3 (en)
ES (1) ES2399670T3 (en)
ME (1) ME01514B (en)
NZ (1) NZ575030A (en)
PT (1) PT2066327E (en)
RS (1) RS52638B (en)
SG (1) SG177219A1 (en)
SI (1) SI2066327T1 (en)
UA (1) UA97249C2 (en)
ZA (1) ZA200901818B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957066B2 (en) * 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CN115487191B (en) * 2016-02-22 2024-05-14 中国科学院上海巴斯德研究所 Quisinostat, a novel high-efficiency antimalarial drug
AU2017298473A1 (en) * 2016-07-20 2019-01-24 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and compositions and uses thereof
CN114409638B (en) * 2022-02-09 2023-02-14 深圳大学 Histone deacetylase 8 selective degradation agent, preparation method and application thereof in antitumor activity
CN115028678A (en) * 2022-07-08 2022-09-09 杭州医学院 Bifunctional molecule based on BCR-ABL protein degradation induced by VHL ligand and preparation method and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG156687A1 (en) * 2004-07-28 2009-11-26 Janssen Pharmaceutica Nv Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase

Also Published As

Publication number Publication date
PT2066327E (en) 2013-02-06
ZA200901818B (en) 2010-05-26
RS52638B (en) 2013-06-28
ES2399670T3 (en) 2013-04-02
UA97249C2 (en) 2012-01-25
NZ575030A (en) 2012-07-27
BRPI0716992A2 (en) 2013-09-17
CN101516374A (en) 2009-08-26
CN101516374B (en) 2013-04-24
SG177219A1 (en) 2012-01-30
DK2066327T3 (en) 2013-02-11
SI2066327T1 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
CL2016002589A1 (en) Use of compound genz-112638 (eliglustat), glucosylceramide synthase inhibitor, in the treatment of gaucher disease and fabry disease (divisional application 201201348).
ECSP056253A (en) PHARMACEUTICAL COMPOSITION CONTAINING A HISTONE DEACETILASE INHIBITOR
ATE516041T1 (en) SYNERGISTIC COMPOSITIONS WITH FK-228
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
UA109786C2 (en) HETEROCYCLIC COMPOUNDS AS IR-RECEPTOR AGONISTS
CL2007001391A1 (en) Compounds derived from substituted pyrrolidines, inhibitors of factor xa and / or inhibitors on serine protease; pharmaceutical composition comprising said compounds; procedure to prepare the pharmaceutical composition; and use of the compounds to prepare a medicamneto with an antithrombotic effect
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
EA200970081A1 (en) COMPOUNDS WITH POTENTIAL ACTIONS WITH RESPECT TO ETIONMIDE ACTIVITY AND THEIR USE
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
RS53056B (en) Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-metoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
GT200600097A (en) PHARMACEUTICAL FORMS WITH IMPROVED PHARMACOCINETIC PROPERTIES
CY1126067T1 (en) FUSIONED PYROLINES THAT ACT AS UBIQUITIN-SPECIFIC PROTEASE 30 (USP30) INHIBITORS
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
ME01514B (en) Histone deacetylase inhibitors with combined activity on class-l and class-ll B histone deacetylases in combination with proteasome inhibitors
ECSP088515A (en) Fungicidal mixtures containing boscalide and pyrimethanil
CY1112122T1 (en) COMPOSITION OF Lipoic acid bullet
CY1108231T1 (en) STABLE SOLID DOSOLOGICAL FORM INCLUDING DESMOPRESIN
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
TW200716577A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
CY1115516T1 (en) Pharmaceutical composition comprising a combination of a non-steroidal anti-inflammatory agent and an antispasmodic agent
CY1109865T1 (en) Valsartan Compositions
TW200716581A (en) Benzothiazol-2-one derivatives as inhibitors of lipases and phospholipases
CL2009001150A1 (en) Compounds derived from n- (2-amino-phenyl) -acrylamides, histone deacetylase inhibitor (hdac); preparation procedure; pharmaceutical composition comprising said compound; and use of the compound for the treatment of cancer.
CL2010001421A1 (en) Use of dronedarone in the preparation of useful medications for the prevention of persistent atrial fibrillation or flutter.
MX2010010876A (en) Substituted piperidines as therapeutic compounds.